Anterior Vitreous Migration after 0.01cc Intravitreal Injection

Intravitreal injection of anti-vascular endothelial growth factor agents such as aflibercept, bevacizumab, and ranibizumab are common treatments for retinal edema and neovascularization related to a number of retinal diseases such as age-related macular degeneration (AMD), retinal vein occlusion, and diabetic retinopathy. A double dose is used for refractory cases where standard dosing is insufficient to control disease progression. We present a case of a rare and potentially serious complication: vitreous prolapse into the anterior chamber following a double dose of intravitreal aflibercept injection. This case highlights the importance of close monitoring for patients who receive intravitreal injections, especially those that receive larger doses of medication.